Prednisone acetate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Prednisone acetate
Accession Number
DB14646  (DBSALT002337)
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • 1,4-Pregnadien-17α,21-diol-3,11,20-trione-21-acetate
  • 21-Acetoxy-17alpha-hydroxypregna-1,4-diene-3,11,20-trione
  • Cortancyl
  • delta'-Dehydrocortisone acetate
  • delta1-Cortisone-21-acetate
  • Prednisone 21-acetate
  • Prednisone-21-acetate
Active Moieties
NameKindUNIICASInChI Key
PrednisoneunknownVB0R961HZT53-03-2XOFYZVNMUHMLCC-ZPOLXVRWSA-N
Categories
UNII
OU93QEL83U
CAS number
125-10-0
Weight
Average: 400.471
Monoisotopic: 400.188588622
Chemical Formula
C23H28O6
InChI Key
MOVRKLZUVNCBIP-RFZYENFJSA-N
InChI
InChI=1S/C23H28O6/c1-13(24)29-12-19(27)23(28)9-7-17-16-5-4-14-10-15(25)6-8-21(14,2)20(16)18(26)11-22(17,23)3/h6,8,10,16-17,20,28H,4-5,7,9,11-12H2,1-3H3/t16-,17-,20+,21-,22-,23-/m0/s1
IUPAC Name
2-[(1R,3aS,3bS,9aR,9bS,11aS)-1-hydroxy-9a,11a-dimethyl-7,10-dioxo-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl]-2-oxoethyl acetate
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(C)=O)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe therapeutic efficacy of (R)-warfarin can be increased when used in combination with Prednisone acetate.
(S)-WarfarinThe therapeutic efficacy of (S)-Warfarin can be increased when used in combination with Prednisone acetate.
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Prednisone acetate.
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Prednisone acetate.
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisone acetate.
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Prednisone acetate.
3,5-diiodothyropropionic acidThe therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Prednisone acetate.
4-hydroxycoumarinThe therapeutic efficacy of 4-hydroxycoumarin can be increased when used in combination with Prednisone acetate.
4-HydroxytestosteroneThe risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisone acetate.
5-androstenedioneThe risk or severity of edema formation can be increased when 5-androstenedione is combined with Prednisone acetate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D08416
KEGG Compound
C14668
ChemSpider
82567
ChEBI
34655
ChEMBL
CHEMBL1507567

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingDiagnosticClinical Stage 0 Cutaneous Melanoma AJCC v8 / Clinical Stage I Cutaneous Melanoma AJCC v8 / Clinical Stage IA Cutaneous Melanoma AJCC v8 / Clinical Stage IB Cutaneous Melanoma AJCC v8 / Clinical Stage II Cutaneous Melanoma AJCC v8 / Clinical Stage IIA Cutaneous Melanoma AJCC v8 / Clinical Stage IIB Cutaneous Melanoma AJCC v8 / Clinical Stage IIC Cutaneous Melanoma AJCC v8 / Clinical Stage III Cutaneous Melanoma AJCC v8 / Clinical Stage IV Cutaneous Melanoma AJCC v8 / Colitis / Malignant Genitourinary System Neoplasm / Pathologic Stage 0 Cutaneous Melanoma AJCC v8 / Pathologic Stage I Cutaneous Melanoma AJCC v8 / Pathologic Stage IA Cutaneous Melanoma AJCC v8 / Pathologic Stage IB Cutaneous Melanoma AJCC v8 / Pathologic Stage II Cutaneous Melanoma AJCC v8 / Pathologic Stage IIA Cutaneous Melanoma AJCC v8 / Pathologic Stage IIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIC Cutaneous Melanoma AJCC v8 / Pathologic Stage III Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v8 / Pathologic Stage IV Cutaneous Melanoma AJCC v8 / Severe or persistent diarrhea1
1Not Yet RecruitingTreatmentClinical Stage III Cutaneous Melanoma AJCC v8 / Clinical Stage III Merkel Cell Carcinoma AJCC v8 / Clinical Stage IV Cutaneous Melanoma AJCC v8 / Clinical Stage IV Merkel Cell Carcinoma AJCC v8 / High-Frequency Microsatellite Instability / Metastatic Basal cell carcinoma / Metastatic Melanoma / Metastatic Skin Squamous Cell Carcinoma / Pathologic Stage III Cutaneous Melanoma AJCC v8 / Pathologic Stage III Merkel Cell Carcinoma AJCC v8 / Pathologic Stage IIIA Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8 / Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 / Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8 / Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 / Pathologic Stage IIID Cutaneous Melanoma AJCC v8 / Pathologic Stage IV Cutaneous Melanoma AJCC v8 / Pathologic Stage IV Merkel Cell Carcinoma AJCC v8 / Unresectable Melanoma1
1RecruitingTreatmentDiffuse Large B-Cell Lymphoma Activated B-Cell Type / Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Lymphoma, Large B-Cell, Diffuse (DLBCL) / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / Leukemias / Untreated Adult Acute Lymphoblastic Leukemia1
1, 2RecruitingTreatmentAggressive Non-Hodgkin Lymphoma / B-cell Non-Hodgkin's Lymphomas / CD20 Positive / Diffuse Large B-Cell Lymphoma Unclassifiable / Intravascular Large B-Cell Lymphoma / Primary Mediastinal (Thymic) Large B-cell Lymphoma / T-Cell/Histiocyte-Rich Large B-Cell Lymphoma / Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma1
1, 2RecruitingTreatmentRecurrent B Acute Lymphoblastic Leukemia / Recurrent T Acute Lymphoblastic Leukemia / Refractory B Acute Lymphoblastic Leukemia / Refractory T Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemia Recurrent / Acute Lymphoblastic Leukaemias (ALL) / BCR-ABL1 Fusion Protein Expression / Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive / Leukemias / Philadelphia Chromosome Positive / T(9;22)1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Prostate Cancer / PSA Level Greater Than or Equal to 0.2 / PSA Progression / Recurrent Prostate Carcinoma1
2Not Yet RecruitingTreatmentAdenocarcinoma, Prostate / Metastatic Hormone Refractory Prostate Cancer / Prostate Carcinoma Metastatic in the Bone / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v81
2Not Yet RecruitingTreatmentAggressive Non-Hodgkin Lymphoma / Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma / Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma / High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements / High Grade B-Cell Lymphoma, Not Otherwise Specified / Indolent Non-Hodgkin's Lymphomas / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mediastinal B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma / Transformed Non-Hodgkin Lymphoma1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult Acute Lymphoblastic Leukemia in Complete Remission / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Leukemias / Philadelphia Chromosome Positive / Untreated Adult Acute Lymphoblastic Leukemia1
2RecruitingTreatmentCastration-Sensitive Prostate Carcinoma / Metastatic Prostatic Adenocarcinoma / Stage IV Prostate Cancer / Stage IVA Prostate Cancer / Stage IVB Prostate Cancer1
3Active Not RecruitingTreatmentChronic Intracranial Subdural Hematoma1
3Not Yet RecruitingTreatmentAngiœdema / Urticarias1
3Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Blasts More Than 25 Percent of Bone Marrow Nucleated Cells / Down Syndrome (DS)1
3RecruitingTreatmentCastration Levels of Testosterone / Metastatic Prostatic Adenocarcinoma / Stage IV Prostate Cancer AJCC v8 / Stage IVA Prostate Cancer AJCC v8 / Stage IVB Prostate Cancer AJCC v81
4CompletedTreatmentTransplantation, Liver1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0235 mg/mLALOGPS
logP2.25ALOGPS
logP2.1ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)12.6ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area97.74 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity106.72 m3·mol-1ChemAxon
Polarizability42.51 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Pregnane steroids
Direct Parent
Gluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-oxosteroids / Delta-1,4-steroids / Alpha-acyloxy ketones / Tertiary alcohols / Alpha-hydroxy ketones / Cyclic ketones / Cyclic alcohols and derivatives
show 4 more
Substituents
Progestogin-skeleton / 20-oxosteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid / 17-hydroxysteroid / Oxosteroid / 11-oxosteroid / Hydroxysteroid / Delta-1,4-steroid / Alpha-acyloxy ketone
show 15 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
acetate ester, 17alpha-hydroxy steroid, steroid ester, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 11-oxo steroid (CHEBI:34655)

Drug created on September 01, 2018 15:34 / Updated on November 02, 2018 07:55